Vevizye Eye
Phase 3Small molecule
Vevizye Eye is one of 25 small molecule programs targeting Eye Disease. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
29 competitors in Eye Disease
#DrugCompanyPhaseTrials
1Chantix
PPrism Pharmaceuticals
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Heparin Sodium
BBaxter Healthcare Corporation
Approved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Empaveli
Apellis PharmaceuticalsApproved
Miebo
BBausch & Lomb Incorporated
Phase 3
AZR-MD-001
AAzura Ophthalmics
Phase 3
Vevizye Eye
MMedical University of Vienna
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vevizye Eye. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMedical University of Vienna